Emerging evidence highlights mitochondrial metabolic reprogramming as a key mechanism enabling colorectal cancer cells to resist chemotherapy and targeted therapies. Tumors adapt through bioenergetic shifts, promoting survival under therapeutic pressure. Understanding these metabolic changes offers promising avenues for developing strategies to overcome resistance and improve treatment efficacy in colorectal cancer patients.